Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

References

• U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004
   Google Scholar
• National Osteoporosis Foundation 2002. America’s bone health: The state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation
   Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2007. Published article online: 25 Jun 2007 doi:10.1111/j.1524–4733.2007.00213.x
   Google Scholar
• Papaioannou A, Ioannidis G, Adachi JD, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003;14:808–13
   PubMed Web of Science ®Google Scholar
• McCombs J, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271–87
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453–60
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922–8
   Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Inter Med 2005;165:2414–9
   PubMed Web of Science ®Google Scholar
• Brankin E, Walker M, Lynch N, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249–56
   PubMed Web of Science ®Google Scholar
• Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99:570–5
   PubMed Web of Science ®Google Scholar
• Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922–8
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–42
   Google Scholar
• Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645–52
   PubMed Web of Science ®Google Scholar
• Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonates therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006;17: 1638–44
   Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914–21
   PubMed Web of Science ®Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14: 259–62
   Google Scholar
• Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859–62
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115: 209–16
   PubMed Web of Science ®Google Scholar
• Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245–56
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don’t continue with treatment. Available from http://www.iofbonehealth.org [Last accessed 7 May 2007]
   Google Scholar
• Zafran N, Liss Z, Peled R, et al. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int 2005;16:1375–83
   PubMed Web of Science ®Google Scholar
• Jakob F, Marin F, Martin-Mola E, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the observational study of severe osteoporosis (OSSO). QJM 2006;99:531–43
   Google Scholar
• Caro JJ, Ishak KJ, Huybrects KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–8
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–22
   PubMed Web of Science ®Google Scholar
• Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int, 2003;14:965–8
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 2007;18:711–9
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023–31
   PubMed Web of Science ®Google Scholar
• Cramer JA, Lynch NI, Gaudin A, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686–94
   PubMed Web of Science ®Google Scholar
• Simonelli C, Burke MS. Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate. Curr Med Res Opin 2006;22:1101–8
   PubMed Web of Science ®Google Scholar
• Dempster DW, Bolognese MA. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis. J Clin Densitom 2006;9:58–65
   PubMed Web of Science ®Google Scholar
• Reid DM. Once-monthly dosing: an effective step forward. Bone 2006:38(Suppl 1):S18–22
   PubMedGoogle Scholar
• Stang P, Morris L, Kempf J, et al. The co-prescription of contra-indicated drugs with statins: continuing potential for increased risk of adverse events. Am J Ther 2007;14:30–40
   PubMedGoogle Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3–12
   PubMed Web of Science ®Google Scholar
• Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;48:2787–92
   PubMed Web of Science ®Google Scholar
• Silverman SL, Chesnut III CH, Amonkar MM, et al. Improved persistence in women treated with once-monthly ibandronate versus weekly bisphosphonates: a first look. J Bone Min Res 2006;21(Suppl 1):S181 [Poster SU335]
   Google Scholar
• Zhang Q, Sautner Z, Shuvayu S. Real life persistency with Fosamax once weekly, Actonel once weekly, and Boniva once monthly among post-menopausal women in the USA. J Bone Min Res 2006;21(Suppl 1):S183 [Poster SA 364]
   Google Scholar
• Cramer JA, Silverman SL, Harley C, et al. Improved 9-month persistence seen in women treated with monthly ibandronate early post launch versus weekly bisphosphonates. Presented at Academy of Managed Care Pharmacy Annual Meeting, San Diego, CA, USA, April 2007
   Google Scholar
• Cramer JA, Sunyecz JA, Derman RJ, et al. Women treated with monthly ibandronate demonstrate improved persistence versus weekly bisphosphonates. Presented at International Society for Pharmacoeconomics and Outcomes Research Annual Meeting, Arlington, VA, USA, May 2007
   Google Scholar
• Kessler RC, Cantrell CR, Berglund P, et al. The effects of copayments on medication adherence during the first two years of prescription drug treatment. J Occup Environ Med 2007;49:597–609
   PubMed Web of Science ®Google Scholar
• Weiss TW, Von Allmen H, Henderson SC, et al. Persistency rates across weekly and monthly bisphosphonates: results from the IMS Health longitudinal Prescription database. J Bone Min Res 2006;21(Suppl 1):S419
   PubMedGoogle Scholar
• Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of non-compliance. Am J Med 2007;120:251–6
   PubMed Web of Science ®Google Scholar
• Ockene IS, Hayman LL, Pasternak RC, et al. Task force #4 – adherence issues and behavior changes: Achieving a long-term solution. J Am Coll Cardiol 2002;40:630–40
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies. Geneva Switzerland: World Health Organization, 2003
   Google Scholar
• Morrison A, Wertheimer AI. Compilation of quantitative overviews of studies of adherence. Drug Inf J 2004;38:197–210
   Web of Science ®Google Scholar
• Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005;22: 313–56
   PubMed Web of Science ®Google Scholar
• Vlasnik JJ, Aliotta SL, DeLor B. Medication adherence: Factors influencing compliance with prescribed medication plans. Case Manager 2005;16:47–51
   Google Scholar
• DiMatteo MR. Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 2004;42:200–9
   PubMed Web of Science ®Google Scholar
• Horne R, Sumner S, Jubraj B, et al. Haemodialysis patients’ beliefs about treatment: Implications for adherence to medication and fluid-diet restrictions. Int J Pharm Prac 2001;9: 169–75
   Google Scholar
• Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17:17–32
   Web of Science ®Google Scholar
• Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002;54:1481–96
   PubMed Web of Science ®Google Scholar
• Butler JA, Peveler RC, Roderick P, et al. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004;19:3144–9
   PubMed Web of Science ®Google Scholar
• Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004;15:38–44
   PubMed Web of Science ®Google Scholar
• Ross S, Walker A, MacLeod MJ. Patient compliance in hyper-tension: role of illness perceptions and treatment beliefs. J Hum Hypertens 2004;18:607–13
   PubMed Web of Science ®Google Scholar
• Brown C, Battista DR, Bruehlman R, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005;43:1203–7
   PubMed Web of Science ®Google Scholar
• Neame R, Hammond A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 2005;44:762–7
   PubMed Web of Science ®Google Scholar
• De Smet BD, Erickson SR, Kirking DM. Self-reported adherence in patients with asthma. Ann Pharmacother 2006;40:414–20
   Google Scholar
• Phatak HM, Thomas J 3rd. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother 2006;40:1737–42
   Google Scholar
• Unson CG, Siccion E, Gaztambide J, et al. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt) 2003;12:1037−45
   PubMed Web of Science ®Google Scholar
• Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy. Am J Med 2006;119:18S–24
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once monthly ibandronate versus once weekly alendronate in a randomized, open label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895–903
   PubMed Web of Science ®Google Scholar
• Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949–60
   PubMed Web of Science ®Google Scholar
• Duarte JW, Bolge SC, Sen SS. An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-International Study. Clin Ther 2007;29:488–503
   Google Scholar
• Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US Study. Health Expect (OnlineEarly articles) doi:10.1111/j.1369–7625.2007.00440.x
   Google Scholar
• Gold DT, Safi W, Trinh H. Patient preferences and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383–91
   Google Scholar
• Keen R, Jodar E, Iolascon G, et al. European women’s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 2006;22:2375–81
   PubMed Web of Science ®Google Scholar
• Hibbard JH. Moving toward a more patient-centered health care delivery system. Health Aff (Millwood) 2004;Suppl Web Exclusive:VAR133–5
   Google Scholar